^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Sulforadex (sulforafan alfadex)

i
Other names: sulforaphane alpha-cyclodextrin, STP2, SFX-01, stabilised sulforaphane, sulforafan cyclodextrin
Associations
Company:
Evgen Pharma, STALICLA
Drug class:
HDAC inhibitor, PTPN11 inhibitor, Androgen receptor antagonist, STAT3 inhibitor
Related drugs:
Associations
9ms
SFX-01 in hospitalised patients with community-acquired pneumonia during the COVID-19 pandemic: a double-blind, randomised, placebo-controlled trial. (PubMed, ERJ Open Res)
At days 8 and 15, respectively, 310 and 42 significant differentially expressed genes were identified between groups (false discovery rate adjusted p1). SFX-01 treatment did not improve clinical status or modulate key Nrf2 targets in patients with CAP primarily due to SARS-CoV-2 infection.
Journal
|
IL6 (Interleukin 6) • IL1B (Interleukin 1, beta)
|
Sulforadex (sulforafan alfadex)
almost3years
Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma. (PubMed, Pharmaceuticals (Basel))
SFX-01 deserves to be considered as an emerging anticancer agent for the treatment of GBM. The possible radio- and chemo sensitization potential of SFX-01 should also be evaluated in further preclinical and clinical studies.
Preclinical • Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
HIF1A expression
|
Sulforadex (sulforafan alfadex)
almost4years
Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer. (PubMed, Oncogene)
Both tamoxifen and fulvestrant increased MFE and aldehyde dehydrogenase (ALDH) activity of patient-derived xenograft (PDX) tumors, which was reversed by combination with SFX-01. Increased expression of these genes after 3 months' endocrine treatment of ER+ patients (n = 68) predicted poor prognosis. Our data establish the importance of STAT3 signaling in CSC-mediated resistance to endocrine therapy and the potential of SFX-01 for improving clinical outcomes in ER+ breast cancer.
Journal
|
ER (Estrogen receptor) • MUC1 (Mucin 1)
|
ER positive
|
tamoxifen • fulvestrant • Sulforadex (sulforafan alfadex)